Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy

BACKGROUND: The immune checkpoint blockade (ICB) targeting programmed cell death-1 (PD-1) and its ligand (PD-L1) has been proved beneficial for numerous types of cancers, including non-small-cell lung cancer (NSCLC). However, a significant number of patients with NSCLC still fail to respond to ICB d...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Lu, Chia-Sing, Lin, Ching-Wen, Chang, Ya-Hsuan, Chen, Hsuan-Yu, Chung, Wei-Chia, Lai, Wei-Yun, Ho, Chao-Chi, Wang, Tong-Hong, Chen, Chi-Yuan, Yeh, Chen-Lin, Wu, Sean, Wang, Shu-Ping, Yang, Pan-Chyr
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Basic Tumor Immunology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692992/
https://ncbi.nlm.nih.gov/pubmed/33243934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001392
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller